SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: 52-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS DOSING

被引：0

作者：

Hall, Stephen ^{[1
]}

Kavanaugh, Arthur ^{[2
]}

McInnes, Iain ^{[3
]}

Mease, Philip ^{[4
]}

Chinoy, Hector ^{[5
]}

Kivitz, Alan ^{[6
]}

Patekar, Manmath ^{[7
]}

Wang, Z. ^{[8
]}

Mpofu, Shephard ^{[9
]}

机构：

[1] Monash Univ, Melbourne, Vic 3004, Australia

[2] Univ Calif San Diego, Sch Med, San Diego, CA USA

[3] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland

[4] Univ Washington, Swedish Med Ctr, Seattle, WA 98195 USA

[5] Univ Manchester, Manchester M13 9PL, Lancs, England

[6] Altoona Ctr Clin Res, Duncansville, PA USA

[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India

[8] Novartis Pharmaceut, E Hanover, NJ USA

[9] Novartis Pharma AG, Basel, Switzerland

来源：

INTERNAL MEDICINE JOURNAL | 2016年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ARA-P88

引用

页码：38 / 39

页数：2

共 50 条

[21] Continued Improvement of Signs and Symptoms in Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study.
Kavanaugh, Arthur
McInnes, Iain B.
Gottlieb, Alice B.
Puig, Lluis
Rahman, Proton
Ritchlin, Christopher T.
Li, Shu
Wang, Yuhua
Doyle, Mittie K.
Mendelsohn, Alan M.
ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4168 - 4168
[22] Secukinumab improves signs and symptoms of active psoriatic arthritis: Results from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using a subcutaneous dosing regimen (FUTURE 2)
Gottlieb, A. B.
McInnes, I. B.
Mease, P.
Kirkham, B.
Kavanaugh, A.
Ligozio, G.
Pricop, L.
Mpofu, S.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S29 - S29
[23] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Baeten, Dominique
Braun, Jurgen
Sieper, Joachim
Dougados, Maxime
Deodhar, Atul A.
Baraliakos, Xenofon
Porter, Brian
Gong, Yankun
Richards, Hanno
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[24] SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A SUBCUTANEOUS DOSING REGIMEN (FUTURE 2)
McInnes, I. B.
Mease, P.
Kirkham, B.
Kavanaugh, A.
Ritchlin, C.
Rahman, P.
Van der Heijde, D.
Landewe, R.
Conaghan, P. G.
Gottlieb, A. B.
Richards, H.
Ligozio, G.
Pricop, L.
Mpofu, S.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 352 - 353
[25] Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
Mease, Philip J.
Chohan, Saima
Fructuoso, Ferran J. Garcia
Luggen, Michael E.
Rahman, Proton
Raychaudhuri, Siba P.
Chou, Richard C.
Mendelsohn, Alan M.
Rozzo, Stephen J.
Gottlieb, Alice
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (09) : 1147 - 1157
[26] CONTINUED IMPROVEMENT OF SIGNS AND SYMPTOMS IN USTEKINUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 52 RESULTS OF A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Kavanaugh, A.
McInnes, I. B.
Gottlieb, A. B.
Puig, L.
Rahman, P.
Ritchlin, C.
Li, S.
Wang, Y.
Doyle, M.
Mendelsohn, A.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 674 - 675
[27] Continued improvement of signs and symptoms in ustekinumab-treated patients with active psoriatic arthritis: week 52 results of a phase 3, multicenter, double-blind, placebo-controlled study
Puig, L.
Kavanaugh, A.
McInnes, I. B.
Gottlieb, A. B.
Rahman, P.
Ritchlin, C.
Li, S.
Wang, Y.
Doyle, M. K.
Mendelsohn, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 53 - 53
[28] Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: 1-year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Ritchlin, Christopher T.
McInnes, Iain B.
Kavanaugh, Arthur
Puig, Lluis
Rahman, Proton
Brodmerkel, Carrie
Li, Shu
Shen, Yaung-Kaung
Doyle, Mittie K.
Mendelsohn, Alan M.
Gottlieb, Alice B.
ARTHRITIS AND RHEUMATISM, 2013, 65 : S127 - S128
[29] SECUKINUMAB SIGNFICANTLY IMPROVES THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN PATIENTS PREVIOUSLY EXPOSED TO ANTI-TUMOUR NECROSIS FACTOR THERAPY AND ANTI-TUMOUR NECROSIS FACTOR-NAIVE PATIENTS: 52 WEEK RESULTS FROM THE PHASE III FUTURE 2 TRIAL
McInnes, Iain
Chinoy, Hector
Kavanaugh, Arthur
Wang, Zailong
Mpofu, Shephard
RHEUMATOLOGY, 2016, 55 : 141 - 141
[30] Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
McInnes, Iain B.
Mease, Philip J.
Kirkham, Bruce
Kavanaugh, Arthur
Ritchlin, Christopher T.
Rahman, Proton
Van der Heijde, Desiree
Landewe, Robert
Conaghan, Philip G.
Gottlieb, Alice B.
Richards, Hanno
Pricop, Luminita
Ligozio, Gregory
Patekar, Manmath
Mpofu, Shephard
LANCET, 2015, 386 (9999): : 1137 - 1146

← 1 2 3 4 5 →